Rob MetzManaging Director, Armour Life Sciences; previous roles include SVP at Horizon Therapeutics

Mr. Metz is the Managing Director of Armour Life Sciences.  Before starting Armour, Metz was at Horizon Therapeutics for 10 years, including the SVP global business operations and general manager Europe. He was responsible for the administration of global business operations and corporate external affairs. Mr. Metz has over 27 years of commercial, external affairs, finance, corporate administration and operations experience in both small and large pharmaceutical and biotechnology organizations. Prior to joining Horizon Pharma, Mr. Metz’s most recent position was vice president, commercial operations for IDM Pharma who manufactured MEPACT® for pediatric osteosarcoma. Prior to joining IDM Pharma, Mr. Metz led commercial operations for NeoPharm, a public rare disease oncology biotechnology company with a phase 3 compound for glioblastoma multiforme. For nearly 13 years, Mr. Metz worked in areas of increasing responsibility at Searle and Pharmacia focusing on product introductions on several products, including Celebrex®, Arthrotec®, Daypro® and Detrol LA®.  Mr. Metz has also held sales and marketing positions at Medpointe Pharma and Reliable Biopharmaceuticals. Mr. Metz has a bachelor’s degree in management/economics with a minor in political science from Marietta College in Marietta, OH.

Click here to sign up for our eNewsletter today!

Please include your Full Name* and Email Address*

*required

If the link above doesn't work, please contact our Admin support at admin@cureswithinreach.org with your Full Name and Email Address to sign up!

 

Cures Within Reach

134 N. LaSalle, #1130
Chicago, IL 60602

info@cureswithinreach.org

All funds donated to Cures Within Reach may be tax deductible for federal income tax purposes. 

Partnership for Cures DBA Cures Within Reach is recognized by the IRS as a 501(c)3 tax-exempt not-for-profit organization, tax ID 20-3620169.

 

Friday the 5th. Copyright 2018 Cures Within Reach.